Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-071.2 manufacturers

Filters

Filters

Filters , active

Country of origin : Japan

Clear all

None products found

pp-071.2

Tablets

Dossier type
EU CTD
Dossier status
Under development
Country of origin
Japan
GMP approvals
EU GMP
Comments
Indication: Advanced or metastatic non-small cell lung cancer harboring EGFR mutations, including patients who have developed resistance to earlier-generation EGFR TKIs (e.g., C797S and other acquired mutations). Clinical stage: Phase I/II clinical development. Modality: Small molecule (oral) Mechanism / Target: Mutant-selective EGFR tyrosine kinase inhibitor designed to inhibit a broad spectrum of activating and resistance EGFR mutations while sparing wild-type EGFR. Route / form: Oral tablets Differentiation: Fourth-generation EGFR inhibitor engineered to overcome key resistance mechanisms (including C797S), with selective inhibition expected to improve tolerability; aims to address unmet need in patients who progress after osimertinib and other standard EGFR-TKI therapies.
Manufacturer #38605

A research-driven pharma company developing therapies across oncology and other major diseases. It advances innovative medicines through global R&D and strategic alliances. The organization emphasizes high-quality manufacturing and patient impact.

 

 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.